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Abstract: Pneumonia, severe sepsis, and acute respiratory distress syndrome (ARDS) are 
frequent complications after head trauma. Recombinant human activated protein C (APC) 
reportedly improves circulation and respiration in severe sepsis, but is contraindicated after head 
injury because of increased risk of intracranial bleeding. A 21-year-old man with severe head 
injury after a car accident was endotracheally intubated, mechanically ventilated, and hemo-
dynamically stabilized before transfer to our university hospital. His condition became com-
plicated with pneumonia, septic shock, ARDS, coagulation dysfunction, and renal failure. In 
spite of intensive therapy, oxygenation and arterial blood pressure fell to critically low values. 
Simultaneously, his intracranial pressure peaked and his pupils dilated, displaying no reflexes to 
light. His antibiotic regimen was changed and ventilation was altered to high frequency oscil-
lations, and despite being ethically problematic, we added APC to his treatment. The patient 
recovered with modest neurological sequelae.
Keywords: activated protein C, acute respiratory distress syndrome, septic shock, severe 
head injury
Introduction
Victims of severe head trauma are prone to remote organ complications.1  Neurogenic 
pulmonary edema (NPE), pneumonia, sepsis, diabetes insipidus, coagulation 
 dysfunction, acute respiratory distress syndrome (ARDS), and multiple organ 
 dysfunctions syndrome (MODS) occur most frequently.1–4 Recombinant human 
 activated protein C (APC), exerting anticoagulant, anti-inflammatory, anti-apoptotic, 
and profibrinolytic effects, reportedly improves cardiovascular and respiratory 
 functions, and increases survival in severe sepsis. However, severe head injury within 
the last 3 months constitutes a contraindication against APC because of increased risk 
of intracranial bleeding.5,6
The aim of this report was to describe the medical and ethical dilemmas when  facing 
a young victim of severe head injury who was threatened by cerebral herniation as his 
condition became complicated with septic shock and ARDS, with lack of response 
to conventional therapy.
Case report
A 21-year-old man was found unconscious hanging in a head down position in 
his overthrown car, approximately 1½ hours after the accident. He was taken by 
ambulance to the local hospital where he arrived with a Glasgow Coma Scale score 
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Figure 1 Head computed tomograms showing skull fractures (A) and scattered 
traumatic subarachnoid hemorrhages (B).





(GCS) of 4. Computed tomography on admission showed 
basilar skull fractures (Figure 1A), traumatic subarachnoid 
hemorrhage, scattered cerebral bleedings (Figure 1B), 
cerebral concussion, and brain edema (not shown in the 
figures). He was endotracheally intubated, mechanically 
ventilated, and hemodynamically stabilized with intravenous 
infusions of norepinephrine and dopamine (Table 1). The 
treatment continued uninterrupted during the transfer via 
air ambulance, staffed with an anesthesiologist and a nurse, 
to the intensive care unit (ICU) of our university hospital, 
where he arrived 7 hours after the accident. Here, his mean 
arterial pressure (MAP), intracranial pressure (ICP), cerebral 
perfusion pressure (CPP = MAP − ICP), and oxygenation 





]), all presented as averages over 24 hours, 
initially displayed normal values (Table 1) and no indication 
for neurosurgical intervention was found.
On hospital day 3, ICP peaked above 30 mmHg (not shown 
in Table 1) accompanied by pupillary dilation and diabetes 
insipidus that were treated with thiopental and  desmopressin, 





 ratio decreased gradually. Despite the fact that 
he was prophylactically treated with cefotaxime because of 
his basilar skull fractures, he contracted bronchopneumonia. 
Since he required continuous hemodynamic support with 
moderate to high doses of norepinephrine and dopamine 
to maintain MAP above 70 mmHg (Table 1), we sus-
pected  septicemia, and gentamycin, erythromycin, and 
hydrocortisone were added to the treatment.
On day 7, his condition worsened with septic shock. 





 ratio and thrombocytes fell (Table 1). Upon 
identification of Staphylococcus aureus in tracheal smears, 
cefotaxime was replaced by imepenem according to the 
resistance test. His chest X-ray (Figure 2) displayed opacities 
consistent with ARDS, and the following day extravascular 
lung water index (EVLWI; Table 1), as assessed by PiCCO 
(Pulsion Medical Systems, Munich, Germany), increased by 
almost three-fold. Simultaneously, diuresis declined from 
200 to 20 mL/hour concomitant with a three-fold increase 
in serum creatinine. ICP peaked above 30 mmHg a second 
time, and both pupils dilated maximally with no reactions 
to light. Veno-venous hemofiltration (Prismaflex® system, 
Gambro, Lund, Sweden) was started and continued over the 




 ratio had fallen to a low 
point of 46 mmHg (day 8), we replaced pressure-controlled 
mechanical ventilation (mean airway pressure of 26 cm 
H
2





 of 1.0) with high frequency oscillatory ventilation 
(HFOV 3100B; VIASYS HealthCare, San Diego, CA) main-
taining unchanged airway pressure and FiO
2
. In addition, he 
received an intravenous infusion of APC (drotrecogin-alpha, 
Xigris®, Eli Lilly and Co, Indianapolis, IN) 24 µg/kg/hour 
over 4 days. Twelve hours later, his MODS regressed; MAP 
and CPP increased from low points of 64 and 45 mmHg, 
respectively, and changes in EVLWI and markers of inflam-
mation and coagulation regressed markedly. ICP decreased 
and hemodynamic  support with norepinephrine and 
 dopamine could be gradually withdrawn (Table 1). On day 
12, HFOV was replaced by conventional pressure-controlled 
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Table 1 Physiological and pharmacological variables
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Ne (ng/kg/minute) 65 72 90 0 50 145 250 480 600 480 150 60 0 0 0
DA (µg/kg/minute) 10 10 20 10 10 0 10 13 13 10 6 0 0 0 0
MAP (mmHg) 72 72 87 91 79 78 75 64 80 76 87 86 81 81 84
ICP 8 9 19 22 15 13 20 22 24 23 22 23 20 13 10
CPP 65 65 70 62 65 65 51 45 54 62 65 57 60 67 65
PaO2/FiO2 (mmHg) 379 332 131 141 123 191 50 46 59 103 195 206 218 210 208
sVRI (dyn × s/cm5/m2) – – – – – – – 560 910 1250 1290 1460 1560 – –
CI (L/min/m2) – – – – – – – 13.7 12.1 10.1 9.7 7 6 – –
CRP (mmol/L) 34 178 194 467 351 192 132 389 446 343 183 118 65 39 22
Leuko (109/L) 14 13 13 12 11 11 18 25 30 28 22 14 11 9 8.3
Trc (1012/L) 267 267 292 292 278 292 304 182 122 137 156 153 299 406 484
eVLWI (mL/kg) – – – – – – – 19 18 14.6 11 8 8 – –
Abbreviations: Ne, norepinephrine; DA, dopamine; MAP, mean arterial pressure; ICP, average intracranial pressure; CPP, average cerebral perfusion pressure, all pressures 
presented as averages over 24 hours; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; sVRI, systemic vascular resistance index; CI, cardiac index; 
CRP, C-reactive protein; Leuko, leukocytes; Trc, thrombocytes; eVLWI, extravascular lung water index.
Figure 2 Chest X-ray displaying opacities consistent with acute respiratory distress 
syndrome (ARDs).
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mechanical ventilation with PEEP 8 cm H
2
O. He was weaned 
off the respirator on day 17 and  transferred to the Department 
of Rehabilitation, from whence he was discharged to his 
home after 2 months. Two years later, a right-sided paresis 
of the oculomotor nerve and a contralateral drop foot were 
his only sequelae.
Written informed consent was obtained from the patient 
for publication of this case report and the accompanying 
images. A copy of the consent is available for review by the 
Editor-in-Chief.
Discussion
It is difficult to predict the outcome of a patient with severe 
head injury who was hanging in a head down  position for 
a lengthy period of time before rescue. Enhanced venous 
 pressure transiently may have increased ICP and  compromised 
his CPP at this early stage of injury. Despite the fact that his 
condition was complicated with pneumonia  followed by 
severe sepsis and ARDS, he survived with modest sequelae 
after receiving intensive therapy including APC.
It is well documented that impaired cerebral blood flow 
after severe head injury leads to reduced brain tissue oxygen 
delivery and lactate accumulation. Reduction of cerebral 
blood flow, or decrease in oxygenation below a certain 
threshold value may escalate brain damage and eventually 
lead to cerebral herniation.7 According to a recent report, 
brain tissue oxygen tension (PbtO
2
) after severe head injury 
can be improved by pharmacologically increasing CPP.8 
Investigators also suggest that therapy based on continuous 
correction of PbtO
2
 is associated with reduced mortality 
and better short-term outcome.9 Concerning our patient, 
it is likely, albeit not proven, that septic shock and severe 
hypoxia combined might have prevented brain oxygenation 
from reaching the PbtO
2
 threshold despite receiving 
vasoconstrictor support at high rates (Table 1).
Victims of severe brain trauma have increased risk of 
developing coagulation disturbances, partly because the brain 
cortex is rich in tissue factor (TF).10 Abundantly released TF 
from the injured brain may induce coagulopathy reminding 
on disseminated intravascular coagulation.11 Independent 
risk factors for coagulopathy in isolated head injuries include 
GCS score ,8, injury severity score .16, hypotension upon 
admission, cerebral edema, subarachnoid hemorrhage, and 
midline shift.11 Our patient met five of these criteria. Although 
his coagulation disturbances most likely resulted from severe 
sepsis, traumatic coagulopathy and brain hypoxia may have 
contributed to his illness.
In severe sepsis, bacterial products activate mediators that 
stimulate inflammation and coagulation. Transcription nuclear 
factor κβ (NF-κβ) and tumor necrosis factor α (TNF-α) are 





released from cells of the immune system and stimulate 
inducible nitric oxide synthase (iNOS) to excessive genera-
tion of NO in endothelial and vascular smooth muscle cells. 
NO contributes to circulatory shock and binds to superoxide 
anion to form peroxynitrite that causes derangements of 
endothelial and epithelial linings resulting in vascular 
leaks and decrease in pulmonary gas exchange typical of 
ARDS.12,13 Inhibitors of iNOS counteract septic shock, but 
do not increase survival from sepsis.14
Bacterial products also release TF from mononuclear cells 
which triggers the extrinsic pathway of the coagulation cascade 
when conjugated with activated factor VII.15 Thus, it might 
be that brain trauma and bacterial products acted together to 
promote the coagulation disturbances in our patient.
Reportedly, 71% of the patients with head injury develop 
pneumonia.3 Aspiration pneumonia, NPE, and ventilator-
associated lung injury are difficult to distinguish from 
ARDS and possibly might have worsened his condition.1,4,13 
However, since his chest X-rays showed no evidence of 
pulmonary edema upon arrival and the subsequent 2 days, 
we considered NPE to be a less likely explanation of his 
lung pathologies.
Application of positive pressure ventilation with PEEP 
might have contributed to the increase in ICP by impeding 
venous return. Even a relatively low PEEP of 6–8 cm H
2
O 
might influence CPP negatively, but with decreasing effect as 
lung compliance decreases.14 However, when his oxygenation 
dropped to the lowest point, instead of increasing PEEP, 
we discussed the idea of treating him with extracorporeal 
membrane oxygenation which was discarded because it 
would require anticoagulant therapy with high doses of 
heparin. Therefore, we changed to high frequency oscillatory 
ventilation, although according to the literature, no increase 
in survival has been noticed in comparison with conventional 
mechanical ventilation.16,17
Since all conventional treatments had failed, the only 
possibility remaining was to perform a decompressive 
craniotomy, but the idea was abandoned because his condi-
tion indicated that he would probably not survive. His parents 
insisted that “something had to be done!”, so we could see 
no option other than facilitating his general circulatory and 
respiratory conditions with the aim to improve his cerebral 
oxygenation.
The protein C Worldwide Evaluation in Severe Sepsis 
(PROWESS) trial had shown that treatment with APC 
resulted in a faster regression of circulatory and respira-
tory dysfunction, and increased survival in patients with 
severe sepsis.5,6 A retrospective study of patients with septic 
shock confirmed that APC rapidly improved vascular tone 
by decreasing the norepinephrine dose required to maintain 
arterial pressure.18 On the negative side, 0.47% of the patients 
randomized to receive APC had suspected intracranial 
hemorrhage during the infusion period.19 Correspondingly, 
a recent meta-analysis reported the rates of intracranial 
hemorrhage to around 0.4% and 0.7% during infusion and 
at 28 days, respectively.20 The abdominal surgery subgroup 
of patients in the PROWESS trial, complicating with severe 
sepsis, had a more than 9% reduction of the absolute risk 
of fatal outcome. The relative risk reduction for 28-day 
mortality in the abdominal surgery patients was 30% and 
in the high-risk patients, as defined by an Acute Physiology 
and Chronic Health Evaluation II score of 25 or greater, 
the relative risk reduction was 40%.21 Literature research 
revealed no controlled studies on the efficacy and safety of 
APC in septicemic patients with a primary head trauma. The 
only hit was the case report of an alcohol-intoxicated man, 
who arrived with subdural hematoma, with a GCS of 14. 
Although his trauma was milder compared with our patient, 
he became critically ill with sepsis and ARDS and survived 
with no rebleeding after treatment including APC.22
We decided to administer APC in spite of the ethical 
dilemma of prescribing a medicine which is formally 
contraindicated.5,6,20 On the other hand, the fact that severe 
sepsis with more than five organ dysfunctions has a mortality 
rate of 85%–90%, presented a strong indication for APC. He 
undoubtedly would face cerebral herniation unless we man-
aged to improve his cerebral oxygenation.23 We discussed the 
therapeutic alternatives and their potential complications openly 
with his parents, who gave their consent to start with APC.
Briefly, APC is an endogenously produced serine 
protease, catalyzed by thrombin/thrombomodulin complex 
when protein C is bound to its endothelial receptor. It acts 
by proteolytic cleavage of activated coagulation factors V 
and VIII and escalates fibrinolysis by inhibiting plasminogen 
activator inhibitor-1.24 APC attenuates inflammation by 
inhibiting the translocation of NF-κβ, suppressing the release 
of proinflammatory cytokines and adhesion molecules, and 
reducing the accumulation of leukocytes in the alveoli.25–27 
Cleavage of the protease-activated receptor-1 by the APC-
endothelial cell receptor complex exerts anti-apoptotic and 
enhanced barrier-protective effects in endothelial cells.28,29 
In rats subjected to infusion of endotoxin, APC inhibits the 
induction of iNOS by decreasing TNF-α production, thereby 
preventing circulatory shock.30
We speculated whether APC might counteract 
coagulopathy after general trauma and after severe head injury 
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in particular.10,11 A prospective study of major trauma patients 
revealed that those with low tissue perfusion upon arrival, 
as indicated by a high base deficit, high  thrombomodulin, 
and low plasma protein C levels, had increased mortality.31 
We found, however, no clinical investigation specifically 
focusing on the effect of APC on coagulopathy after isolated 
head trauma. We assume that our patient, at least transiently, 
suffered from low tissue perfusion, but thrombomodulin and 
protein C levels were not determined.
As of today, information is sparse as to whether APC could 
be of potential benefit after traumatic brain injury.  Investigators 
recently noticed that after standardized  cortical trauma in 
mice, APC reduced the volume of lesions and improved the 
neurological outcome. They also compared wild-type APC 
with an APC analog with reduced anticoagulant and normal 
cytoprotective activity for late treatment. The APC analog 
displayed greater neuroprotective effect and less intracranial 
bleeding compared with wild-type APC.32,33
Whether APC, which was primarily administered against 
septic shock, also acted beneficially on brain injury per se, 
remains elusive. Since his condition improved with a decrease 
in ICP, we believe that APC through its improvement of 
circulation and respiration might have  contributed to his 
recovery that left him with modest sequelae only.  However, 
his recovery inspires us to suggest a future controlled 
randomized trial of the efficacy and safety of an APC analog 
with reduced anticoagulant and maintained cytoprotective 
activity, if it will be available, in patients with MODS after 
severe head injury.
Conclusion
Although ethically controversial because of increased risk of 
intracranial bleeding, APC should not be rejected as part of 
a rescue therapy in cases of severe head injury complicating 
with septic shock and ARDS not responding to conventional 
therapy. However, as a general rule, decisions to treat should 
be taken based on evidence from controlled randomized trials 
and not from animal experiments or case reports.
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